Search
Ribavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalCombination therapy of ribavirin and [DB00008] results in the SVR of 44% in patients with genotype 1 infection and 70% in patients with genotype 2-6. … in HCV genotype 4 patients [L852].
Mixtures: Rebetron Solution (albumin (human) Free) (18 Miu Multi-dose Pen / 200mg Capsules)Conestat alfa
go.drugbank.com/drugs/DB09228ApprovedAdditionally, C4 and C2 cleavage occurs resulting in auto-activation of the complement system. … Intravenous replacement of C1 esterase inhibitor results in reversal of acute symptoms of HAE.
Categories: Drugs Used in Hereditary AngioedemaChlorothiazide
go.drugbank.com/drugs/DB00880ApprovedInvestigationalVet approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
Risankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.
Products: SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML, Skyrizi solution for injection in pre-filled pen 150MG/MLAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalAdagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.
TrenibotulinumtoxinE
go.drugbank.com/drugs/DB19082ApprovedTrenibotulinumtoxinE is a botulinum neurotoxin serotype E, produced in *Clostridium botulinum*, used for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. … [L64118] It is the first and only rapid-onset, short-duration botulinum neurotoxin serotype E approved in Europe.[L64118]
Synonyms: BOTULINUM NEUROTOXIN SEROTYPE E (BONT/E) (EB-001), BONTOXILYSIN-EEstetrol
go.drugbank.com/drugs/DB12235ApprovedInvestigationalEstetrol is the first new estrogen introduced to the USA in over 50 years and is the first approved estetrol product in the world. … [L33179] In Canada, Nextstellis was approved for use in March 2021; it was developed by Mithra and is marketed by Searchlight Pharma.[L33209]
Cariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigationalCariprazine gained its first global approval in the US in September 2015 [A3941] and was later approved by Health Canada in April 2022. … Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.
Synonyms: trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N’,N’-dimethylurea hydrochlorideDeslanoside
go.drugbank.com/drugs/DB01078ApprovedDeacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.
Categories: Compounds used in a research, industrial, or household settingVestronidase alfa
go.drugbank.com/drugs/DB12366ApprovedInvestigationalIn clinical trials, vestronidase alfa treatment demonstrated improvement and stabilization in motor symptoms by increasing the patients' ability to walk longer distances in comparison to treatment with … Vestronidase alfa was FDA-approved on November 17th, 2017 under the trade name Mepsevii as an intravenous infusion for the treatment of pediatric and adult patients.